Dr. Forster Discusses the ATLANTIS Study in Small-Cell Lung Cancer
Martin Forster, MD, medical oncologist, University College London Hospitals, discusses the ATLANTIS study in small-cell lung cancer.
Martin Forster, MD, medical oncologist, University College London Hospitals, discusses the ATLANTIS study in small-cell lung cancer (SCLC).
The ongoing ATLANTIS trial is investigating lurbinectedin (PM01183) plus doxorubicin versus cyclophosphamide, doxorubicin and vincristine or topotecan in patients with SCLC.
Initial responses have been seen with lurbinectedin as a single agent in patients with platinum-sensitive patients.
Related Videos
Related Content
